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Abstract
Aims/hypothesis This is an update of the results from the previous report of the CORONADO (Coronavirus SARS-CoV-2 and
Diabetes Outcomes) study, which aims to describe the outcomes and prognostic factors in patients with diabetes hospitalised for
coronavirus disease-2019 (COVID-19).
Methods The CORONADO initiative is a French nationwide multicentre study of patients with diabetes hospitalised for
COVID-19 with a 28-day follow-up. The patients were screened after hospital admission from 10 March to 10 April 2020.
We mainly focused on hospital discharge and death within 28 days.
Results We included 2796 participants: 63.7%men, mean age 69.7 ± 13.2 years, median BMI (25th–75th percentile) 28.4 (25.0–32.4)
kg/m2. Microvascular and macrovascular diabetic complications were found in 44.2% and 38.6% of participants, respectively. Within
28 days, 1404 (50.2%; 95% CI 48.3%, 52.1%) were discharged from hospital with a median duration of hospital stay of 9 (5–14) days,
while 577 participants died (20.6%; 95% CI 19.2%, 22.2%). In multivariable models, younger age, routine metformin therapy and
longer symptom duration on admissionwere positively associatedwith discharge. History ofmicrovascular complications, anticoagulant
routine therapy, dyspnoea on admission, and higher aspartate aminotransferase, white cell count and C-reactive protein levels were
associated with a reduced chance of discharge. Factors associated with death within 28 days mirrored those associated with discharge,
and also included routine treatment by insulin and statin as deleterious factors.
Conclusions/interpretation In patients with diabetes hospitalised for COVID-19, we established prognostic factors for hospital
discharge and death that could help clinicians in this pandemic period.
Trial registration Clinicaltrials.gov identifier: NCT04324736
Keywords Admission plasma glucose . COVID-19 . Death . Diabetes . Discharge . HbA1c . Home discharge . Mechanical
ventilation
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Abbreviations
ARB Angiotensin-2 receptor blockers
AST Aspartate aminotransferase
CCB Calcium channel blocker
COPD Chronic obstructive pulmonary disease





DPP-4 Dipeptidyl peptidase 4
ICU Intensive care unit
MRA Mineralocorticoid receptor antagonist
OSA Obstructive sleep apnoea
SARS-CoV-2 Severe acute respiratory syndrome
coronavirus-2
Introduction
Soon after the coronavirus disease-2019 (COVID-19) pandemic
outbreak, diabetes was rapidly identified as a risk factor for poor
outcome [1, 2]. Diabetes has been previously recognised as a
major risk factor for mortality in people infected with either the
2009 H1N1 pandemic influenza or the Middle East respiratory
syndrome-related coronavirus (MERS-CoV) [3, 4]. More recent-
ly, diabetes consistently appeared as one of the major comorbid-
ities associated with COVID-19 [1, 2, 5, 6].
Moreover, diabetes has been shown to be associated with
worse prognosis. Indeed, the prevalence of diabetes was two- to
threefold higher in patients admitted to intensive care units (ICUs)
compared with those with less severe disease and the mortality
rate was consistently higher in patients with diabetes [1, 2, 7–10].
Altogether, diabetes received considerable attention and was very
often considered as a top risk factor for fatal COVID-19. In this
context, contracting COVID-19 is a major source of worry in
people with diabetes [11–13].
Diabetes-related worse COVID-19 prognosis has been exten-
sively documented so far. In a short-term interim analysis of the
CORONADO (Coronavirus-SARS-CoV-2 and Diabetes
Outcomes) study, we showed that, in 1317 people with diabetes
admitted for COVID-19, poor outcomes within 7 days were inde-
pendently associatedwith BMI, age, diabetic complications, treat-
ed obstructive sleep apnoea (OSA), and some biological features
[14]. However, to the best of our knowledge, no study has specif-
ically focused on factors associated with favourable prognosis
enabling hospital discharge in patients with diabetes admitted
for COVID-19 infection.
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Here, compared with our previous report, we expand our
data to a larger sample size and a longer duration of follow-up.
The current study describes the complete results of the
CORONADO study, a French nationwide multicentre obser-
vational study aimed at identifying the clinical and
biological features associated with disease severity and
mortality in patients with diabetes hospitalised for
COVID-19, with a specific focus on the clinical and
biological characteristics of patients discharged home
or to a long-term care facility by day 28.
Methods
Study design and participants The design of the CORONADO
study has been previously reported [14]. The aim of the studywas
to describe the phenotypic characteristics and prognosis of
patients with diabetes presenting with COVID-19 between 10
March and 10 April 2020, in 68 French hospitals. Inclusion
criteria were: (1) hospitalisation in a dedicated COVID-19 unit
for biologically attested (PCR for severe acute respiratory
syndrome coronavirus-2 [SARS-CoV-2]) and/or clinically/radio-
logically attested COVID-19 (i.e. as ground-glass opacity and/or
crazy paving on chest computed tomography [CT] scan); (2)
personal history of diabetes or newly diagnosed diabetes on
admission (i.e. HbA1c ≥6.5% [48 mmol/mol] during
hospitalisation).
The study was designed in accordance with the Declaration of
Helsinki and conducted in accordance with French legislation
with approvals obtained from one local and two national commit-
tees: the local ethics committee (IRB/IEC – GNEDS; Ref.
CORONADOV2), the CEREES (n° INDS:1544730) and the
CNIL (DR-2020-155/920129). The latter waived informed
consent owing to the purely observational approach using only
retrospective data [14].
This article follows the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) reporting
guidelines for cohort studies.
Data collectionData collectionwas retrospectively performed by
clinical research associates and physicians in participating centres
frommedical files. They systematically reviewed themedical files
of all COVID-19 inpatients, selected those with diabetes and, if
necessary, contacted the patient’s general and/or specialist practi-
tioners, regular pharmacist and biomedical laboratory. Collected
data included clinical characteristics prior to admission including
complications, comorbidities and routine treatments. Moreover,
COVID-19-related clinical, radiological and biological character-
istics were collected on admission. Regarding liver enzymes, the
upper limit of normal was different between centres (see electron-
ic supplementary material [ESM] Table 1).
Patient follow-up and clinical outcomes The composite prima-
ry outcome was combined tracheal intubation for mechanical
ventilation and/or death within 7 days of admission. Participants
discharged before day 7 were systematically contacted to check
for the non-occurrence of these events on day 7.
Secondary outcomes included death, tracheal intubation,
admission to ICUs and hospital discharge. A secondary time
point was considered at day 28 for all patients alive and not
discharged by day 7 in order to consider outcomes
between admission and day 28. Outcomes were no
longer collected after discharge on day 7 or later and
no further follow-up was organised after day 28.
Moreover, patients transferred to rehabilitation centres
or to other hospitals were classified as ‘transferred’
and no follow-up information could be ascertained after
the transfer. Those who remained in the hospital of their
initial admission were classified as ‘in-hospital’. Only
those returning home or to a long-term care facility
were classified as ‘discharged’.
The current analysis mainly focused on hospital discharge
and death within 28 days of follow-up.
Statistical analyses Quantitative data were expressed as mean
± SD or median (25th–75th percentile). Categorical variables
were given as n (%) of participants. We described covariates
according to time of admission, splitting data prior to and on
admission, which corresponds to a clinician’s perspective. As
specified in the protocol, the main objective of the study was
descriptive. Originally, we calculated that, with a population
of 300 participants and an attrition rate of 20%, an occurrence
of 16% of the composite outcome would give a 95% CI equal
to 11.7, 21.1% using the Clopper–Pearson estimate. In this
analysis, we considered two main outcomes: hospital
discharge and death within 28 days. The composite outcome
(death and/or tracheal intubation) is only presented as ESM
(ESM Tables 2–4).
Univariate logistic regression models were used to calcu-
late ORs associated with study outcomes. Natural-log trans-
formation was consistently considered in order to complywith
linearity assumptions, which applied for diabetes duration,
BMI and biological features.
Multivariable logistic regression models were used to
assess the association between clinical and biological features
and study outcomes (discharge and death within 28 days and
primary outcome within 7 days). A standardisation process (z
score) was also applied to quantitative variables to allow for
direct comparison. Covariates included in the model were
chosen according to a clinician’s point of view, based on
background knowledge. The multivariate model included
elementary clinical characteristics (sex, age, BMI); the
patient’s history (hypertension, micro- and macrovascular
complications, chronic obstructive pulmonary disease
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[COPD], treated OSA); routine medication (metformin, insu-
lin, angiotensin-2 receptor blockers [ARBs] and/or ACE
inhibitors and/or mineralocorticoid receptor antagonists
[MRAs], statins, anticoagulation therapy); symptoms on
admission (time between symptom onset and hospital admis-
sion, dyspnoea); and biological features (eGFR [determined
using the CKD-EPI formula], aspartate aminotransferase
[AST], white cell count, platelets, C-reactive protein [CRP]).
Of note, the event-per-variable was always ≥10 in the main
multivariable analyses.
Sensitivity analyses were performed for all multivari-
able models. First, we restricted the study population to
the 2547 participants (91.1%) with a positive SARS-CoV-
2 PCR. Second, we restricted the study population to the
1551 participants (55.5%) with admission plasma glucose
data available.
All statistical tests were two-sided with a type 1 error set at
5%. All analyses were performed on available data, without
imputation, and using statistical software R version 4.0.0
(https://cran.r-project.org).
Results
Study population and characteristics of COVID-19 The differ-
ent centres originally screened 2951 patients suspected of
hospitalisation or prolongation of hospitalisation related to
COVID-19 between 10 March and 10 April 2020, with a
diagnosis of diabetes mellitus (see flow diagram, ESM Fig.
1). After further investigations, 97 patients (3.3%) were ruled
out for not meeting inclusion criteria (including 47 patients
without diabetes mellitus and 35 without COVID-19). From
the 2854 patients meeting inclusion criteria, 58 patients
(2.0%) were excluded from the present analysis because of
at least one unavailable key outcome, including seven with
missing data on death during hospital stay and 25 with miss-
ing data on discharge. Finally, 2796 patients were analysed.
Among those participants, 1317 (47.1%) were previously
described in a recent interim analysis [14].
The baseline characteristics of the study participants are
detailed in Tables 1 and 2. Briefly, participants were mostly
male (63.7%), classified as having type 2 diabetes (88.2%), of
Europid origin (58.1%), and with a mean ± SD age of 69.7 ±
13.2 years, a median (25th–75th percentile) BMI of 28.4
(25.0–32.4) kg/m2 and a median (25th–75th percentile)
HbA1c value of 60.7 mmol/mol (50.8–74.9 mmol/mol)
(7.7% [6.8–9.0%]). On admission, a positive SARS-CoV-2
PCR was found in 2547/2705 (94.2%) patients and median
(25th–75th percentile) CRP was 86 (40–148) mg/l.
COVID-19-related clinical outcomes are detailed in ESM
Table 5 and the timeframe for study outcomes is presented in
Fig. 1.
Discharge within 28 days As shown in Fig. 1, 50.2% of the
CORONADO participants were discharged within 28 days.
Their median (25th–75th percentile) length of stay before
discharge was 9 (5–14) days with 156/1404 (11.1%)
discharged in the first 3 days following admission. Since the
management of COVID-19 has been rapidly evolving, we
analysed the length of stay according to three consecutive
admission periods (see ESM Fig. 2a,b) and highlighted no
statistical difference, with 18/234 (7.7%), 104/886 (11.7%)
and 34/284 (12.0%) patients discharged in the first 3 days
who were admitted 10–19 March, 20–30 March, and 31
March to 10 April, respectively (p = 0.18).
The characteristics of the participants discharged by day 28
are presented in Table 1 and Table 2. Briefly, women were
more likely than men to be discharged. Older age was associ-
ated with a lower chance of discharge (for a 1-year increment,
OR 0.96; 95% CI 0.95, 0.97). Hypertension, micro- or
macrovascular diabetic complications, heart failure and
COPD were also associated with a lower chance of discharge.
Regarding routine therapy, metformin and dipeptidyl peptidase
4 (DPP-4) inhibitors were associated with a higher chance of
discharge, whereas insulin, diuretics, β-blockers and
anticoagulation therapy were associated with a lower chance.
As regards patient characteristics on admission, dyspnoea,
plasma creatinine, and almost all biological findings associat-
ed with an inflammatory profile (including higher AST,
higher white cell and lower lymphocyte cell count, and higher
CRP) were significantly associated with a lower chance of
discharge.
The results of multivariable analysis of discharge within
28 days are presented in Fig. 2 (see ESM Table 6 for results
of the raw multivariable analysis, without transformation).
Predictors of discharge on day 28 were younger age, routine
metformin therapy and longer time between symptom onset
and hospital admission. Conversely, history of microvascular
complications, routine anticoagulant therapy, dyspnoea,
higher AST, white cell count and CRP levels were associated
with a reduced chance of discharge.
In the sensitivity analysis on the complete-case population
restricted to the patients with positive SARS-CoV-2 PCR (n =
1249) or admission plasma glucose available and added to the
model (n = 761), using the same variables as those used in the
multivariable model applied to the whole population, we
found very similar results (ESM Table 7).
Death within 28 days Characteristics prior to admission of
those patients who died within 28 days are presented in
Table 3. In age-adjusted analysis, male sex, longer duration
of diabetes, as well as history of micro- and macrovascular
complications, heart failure and COPD were significantly
associated with death.
When considering the characteristics on admission,
COVID-19 symptoms, fever and dyspnoea were positively
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associated with death within 28 days after adjustment for age
(Table 4). Nearly all biological covariates reflecting COVID-
19 severity were associated with death, including admission
plasma glucose, plasma creatinine, AST, white cells, lympho-
cyte and platelet counts and CRP level.
Multivariable models for death within 28 days are present-
ed in Fig. 2. After multiple adjustment, older age, history of
microvascular complications, insulin and statin routine medi-
cation, dyspnoea on admission, higher AST, higher white cell
count, lower platelet count and higher CRP level were asso-
ciated with a greater risk of death when routine metformin
therapy and a longer time between symptom onset and hospi-
tal admission were negatively associated with death. In a
sensitivity analysis restricted to participants with positive
SARS-CoV-2 PCR or those with available admission plasma
glucose, the results were similar (ESM Table 8).
Outcomes within 7 days In the first 7 days following hospital
admission, the prespecified primary outcome (tracheal intuba-
tion for mechanical ventilation and/or death) occurred in 800
(28.6%) participants and death in 312 (11.2%). The phenotyp-
ic characteristics of CORONADO participants according to
the primary outcome are described in ESM Table 2 (features
prior to admission) and ESM Table 3 (features on admission).
Multivariable analysis (n = 1335, ESM Table 4) identified
dyspnoea on admission, higher AST, higher white cell count,
lower platelet count and higher CRP level as positively asso-
ciated and metformin use as negatively associated with the
primary outcome. The same results were observed in a
sensitivity analysis on the complete-case population restricted
to patients with positive PCR (n = 1249) or with available
plasma glucose on admission (n = 761) (ESM Table 4).
Discussion
CORONADO is the first registered study that specifically
aimed to describe the phenotypic characteristics and to iden-
tify prognostic factors in patients with diabetes hospitalised
for COVID-19. The present analysis reports the results of
the complete CORONADO study totalling 2796 participants
from 68 centres with complete follow-up up to day 28. We
noted that one out of two CORONADO participants returned
home by day 28. Younger age, routine metformin therapy and
a longer duration of symptoms before admission were inde-
pendently associated with such a favourable outcome, while a
history of microvascular complications, routine anticoagulant
therapy, dyspnoea and biological markers of COVID-19
severity were associated with a reduced chance of discharge
by day 28. In contrast, BMI, HbA1c and other comorbidities
were not associated with this outcome. Results for death with-
in 28 days mirrored the factors found for hospital discharge in
an opposite way.
Regarding death, we reported amortality rate of 11.2%with-
in 7 days which reached 20.6% within 28 days. These findings
can be compared to international reports. In a meta-analysis
considering a majority of Chinese studies, in-hospital mortality
was encountered in 299/2571 (11.6%) but the severity of illness
Fig. 1 Distribution of patient outcomes according to time since hospital admission. Population size was N = 2796
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in those patients is questionable since they were admitted early
in the pandemic [15]. In contrast, in a retrospective cohort anal-
ysis of 1126 patients with diabetes hospitalised with COVID-
19 at a large academic medical centre in New York City, the
mortality rate was 33.1%, much higher than our findings. The
higher prevalence of cardiovascular and chronic kidney disease,
both independently associatedwithmortality, could explain this
discrepancy [16]. In the UK, Docherty et al reported data on
20,133 hospitalised COVID-19 patients including 4949 with
diabetes (1299 with and 3650 without diabetes complications)
[17]. This study is consistent with our findings, with a popula-
tion of similar age (mean age: 73 years in the UK study vs
70 years in CORONADO). In-hospital death occurred in
1080/3650 patients with uncomplicated diabetes (29.6%) and
in 389/1299 (29.9%) with complicated diabetes, although the
observational period is not directly mentioned. We therefore
believe that our data are generalisable, at least to people living
with diabetes in Europe.
With regard to prognostic factors of death, our results
are in accordance with three nationwide studies from the
UK. Holman et al evidenced that death was associated
with age and male sex, but also with deprivation, which
is not available in our report, while a U-shaped relation-
ship was found for HbA1c [18]. OpenSAFELY was able
to examine, through electronic health record analysis, a
population of more than 17 million people linked to more
than 10,000 COVID-related deaths and showed that death
was associated with male sex, age, BMI, and a clearly
graded effect of HbA1c: the higher the HbA1c the greater
the risk of death [19], while we could not show this for
HbA1c in our more limited dataset. More recently Knight
et al computed a prognostic score of in-hospital death
considering a population with over 20% of people affect-
ed by diabetes. In accordance with our findings, they also
identified age, sex and CRP as prognostic factors while
other factors were not directly available in our study [20].
However, these papers did not mention hospital discharge
and consider general populations and mostly ambulatory
patients, which is at variance with what was performed in
the CORONADO study.
DISCHARGE
Favours no discharge favours discharge Favours survival Favours death
DEATHPatient characteristics OR (95%CI) OR (95%CI)
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Fig. 2 Multivariable analysis of hospital discharge and death within
28 days: covariates prior to and on admission. Models were applied to
1355 participants yielding 728 discharges (53.7%) and 225 deaths within
28 days (16.6%). Regarding quantitative variables: all were natural-log
transformed, except for age and BMI, and the ORs correspond to an
increase of 1 SD after standardisation. The model on the left uses
discharge within 28 days as the dependent variable, and the model on
the right uses death within 28 days. Microvascular complication was
defined as history of one or more of the following: diabetic kidney disease
and/or severe diabetic retinopathy and/or history of diabetic foot ulcer.
Macrovascular complication was defined as history of one or more of the
following: ischaemic heart disease (acute coronary syndrome and/or
coronary artery revascularisation) and/or cerebrovascular disease (stroke
and/or transient ischaemic attack) and/or peripheral artery disease (ampu-
tation owing to ischaemic disease and/or lower limb artery
revascularisation) MRAs include spironolactone and eplerenone; eGFR
was determined by the CKD-EPI formula. ULN, upper limit of normal
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It should be noted that the numbers of patients who died
during follow-up were close to being equally distributed with-
in the first 7 days (11.2%) and day 8 to day 28 (9.5%), while
tracheal intubation for mechanical ventilation occurred, as
expected, predominantly within 7 days after admission (532/
556, 95.6%). These findings are in line with the previously
described clinical course of the disease. Thus, in 54 non-
survivors of COVID-19 from Wuhan, China, the median
hospital length of stay was of 7.5 days [2]. Moreover,
Argenziano et al found that 71.6% of 225 patients were
intubated within the first 3 days following admission to the
emergency room [7].
In addition to data on in-hospital death, we believe data on
home discharge within 28 days should be reported since it is a
positive result of value for both patients and physicians and it
provides another perspective on COVID-19. Our data support
the reasonable opinion that factors associated with home
discharge mirror, as expected, those associated with the severity
of the disease. This turned out to be true with biological covar-
iates on admission such as plasma creatinine, AST and CRP,
with a particular importance for admission blood glucose.
While our multivariable analyses were performed on a
limited number of participants, owing to missing data, the
current study helped to establish the relative contribution of
admission blood glucose on the risk of death and on the
chance of discharge. We found that chronic glycaemic control
assessed with pre-admission or admission HbA1c did not
impact on the fate of COVID-19 patients, with no significant
association with death or with discharge within 28 days. In
contrast, increased admission plasma glucose concentration
was a strong predictor of death and, consistently, of a lower
chance of discharge. We have recently commented on two
interesting studies reporting on the question of admission plas-
ma glucose in COVID-19 and community-acquired pneumo-
nia [21, 22]. This association between blood glucose control
and prognosis in hospitalised COVID-19 patients has also
been observed in patients without previously diagnosed diabe-
tes [23–25]. Furthermore, other studies suggest that blood
glucose control during hospitalisation is associated with
COVID-19 outcomes [26, 27]. However, due to the observa-
tional design of our study and others, no conclusion regarding
causality can be drawn. The relationship between admission
plasma glucose and severe conditions was previously
established in many clinical situations, including, for instance,
heart failure, stroke or myocardial infarction [28–31]. In none
of these situations did strict metabolic control consistently
decrease mortality.
Our results also establish an association between routine
therapy and chance of discharge or risk of death.
Interestingly, metformin was associated with favourable
outcomes (both lower risk of death and greater chance of
discharge within 28 days). Conversely, statin use was associ-
ated with higher risk of death and anticoagulation therapy with
a reduced chance of discharge. The findings with statins are
surprising since the in-hospital use of this drug class has been
recently associated with a lower risk of 28-day mortality in
13,981 patients with COVID-19 from China [32].
Unexpectedly, we also found a higher risk of primary
outcomes within 7 days (but not of other outcomes) in patients
taking calcium channel blockers (CCBs) on admission.
However, whether these findings reflect a significant negative
effect or a mere indication bias would require more sophisti-
cated adjustment methods such as specific propensity score,
which is beyond the scope of the current paper.
Study limitations Some limitations must be acknowledged
here. First, we focused on hospitalised COVID-19 cases and
our results cannot be generalised to all COVID-19 patients
with diabetes, especially those with a less severe form of the
disease. Second, we focused on those discharged to their
home or to a long-term care facility. Since insufficient ascer-
tainment was available from those transferred to another
hospital or rehabilitation centre, our figures are conservative
even if we believe that transfer is unlikely to lead to short-term
discharge before day 28. Third, it can also be argued that the
28-day observation period was too short with 12.2% of admit-
ted participants requiring more prolonged hospitalisation in
the same hospital. Nonetheless, this 28-day mark is a well-
established milestone, particularly in an ICU setting, and
further outcomes probably reflect other medical issues.
Fourth, for a non-negligible number of patients (249/2796,
8.9%), SARS-CoV-2 PCR was not available or negative.
However, the main analyses were replicated in the subset with
a positive SARS-CoV-2 PCR showing similar results. Fifth,
due to the exploratory nature of the results, our work must be
read as a post hoc analysis. The chosen multivariable
approach infers, by design, obvious limitations: a lack of
control of type 1 error; the transformation of quantitative vari-
ables, which was needed to comply with the statistical
assumption of the model, at the expense of less natural clinical
interpretation; and the adjustment set, based on background
knowledge, which is associated with a risk of overfitting.
Sixth, although specific treatment for COVID-19, such as
corticosteroid, immunotherapy or antiviral agents could influ-
ence prognosis, data about such treatment given during
hospitalisation were not available in our study. Ultimately,
our results are hampered by missing data, such as HbA1c.
Nevertheless, the CORONADO study is, to date, the most
accurate study providing such information. The inclusion of
additional studies of a similar nature would help to increase
our confidence in observations with significant missing data.
The study strengths must also be acknowledged, such as the
originality of the medical question leading to the CORONADO
initiative and the inclusion of participants with a nationwide
coverage, in any department of a participating hospital, includ-
ing the ICU and medical units. We also recorded patients’
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phenotypic characteristics in a structured manner and did not
solely rely on medico-administrative databases.
In conclusion, the CORONADO study refined the pheno-
types of hospitalised COVID-19 patients with diabetes. To
summarise, younger age, routine metformin therapy and longer
symptom duration on admission were positively associated
with discharge. History of microvascular complications, antico-
agulant routine therapy, dyspnoea on admission, and higher
AST, white cell count and CRP levels were associated with a
reduced chance of discharge. Deleterious and protective factors
for discharge mirrored those for death by day 28, respectively.
The identification of favourable variables associated with
hospital discharge and deleterious variables associated with
death can lead to patient reclassification and help to use
resources adequately according to individual patient profile.
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